Survival of patients with advanced ovarian carcinoma treated with Penberol.

The authors report their results of treatment in patients with ovarian carcinoma (stages III and IV, FIGO classification) with the cytostatic Penberol (cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid), synthesized at the Research Institute for Pharmacy and Biochemistry in Prague. The present communication links on the paper published in 1980. Out of 20 patients treated with Penberol, 11 have responded by a complete remission persisting for 8-55 months; in five of them the remission has not finished as yet. Both in the experiment and in the clinic the behavior of Penberol differs from that of classical cytostatics, and the observations evaluated so far attest to antitumor activity based on inhibition of the cell energetic metabolism.